Scholars@Duke
Thomas Lee Ortel

Thomas Lee Ortel

Chief, Division of Hematology in the Department of Medicine
Medicine, Hematology
thomas.ortel@duke.edu
Duke Box 3422, Durham, NC 27710
0563 Stead Bldg, Durham, NC 27710

Scholarly Works - Journal articles

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Journal article Arthritis Care Res (Hoboken) · May 2026 OBJECTIVE: The 2023 American College of Rheumatology (ACR)/EULAR antiphospholipid syndrome (APS) classification criteria aim to identify patients with a high likelihood of APS for research. Phases I/II of our four-phase methodologic approach resulted in 27 ... Full text Link to item Cite

Development and validation of a EULAR disease activity score in antiphospholipid syndrome.

Journal article Ann Rheum Dis · March 2026 OBJECTIVES: To develop and validate a European Alliance of Associations for Rheumatology (EULAR) disease activity score in antiphospholipid syndrome (EAPSDAS). METHODS: Twenty-four Task Force members and an international group of 53 antiphospholipid syndro ... Full text Link to item Cite

Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.

Journal article Am J Obstet Gynecol · January 2026 Venous thromboembolism contributes to approximately 10% of pregnancy-associated deaths in the United States, with the highest incidence rate in the immediate postpartum period. Cesarean deliveries are associated with 4-fold relative risk of venous thromboe ... Full text Link to item Cite

Anticoagulation in malignancy: the patient who bleeds and clots simultaneously.

Journal article Hematology Am Soc Hematol Educ Program · December 5, 2025 Patients with active malignancy frequently require anticoagulation for a variety of indications, including thrombosis, atrial fibrillation, or mechanical heart valves. Cancer-associated thrombosis is associated with significant morbidity and mortality and ... Full text Link to item Cite

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Journal article Curr Rheumatol Rep · November 26, 2025 PURPOSE OF REVIEW: An international multi-disciplinary initiative resulted in the development of 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria to identify patients with high likelihood of APS for research. Phase I/II resulted in 27 ... Full text Link to item Cite

Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism.

Journal article J Thromb Haemost · November 2025 BACKGROUND: Guidelines recommend extended anticoagulation after a first unprovoked venous thromboembolism (VTE) for individuals at low risk of bleeding. However, racial disparities in bleeding risks during extended treatment remain understudied. OBJECTIVES ... Full text Link to item Cite

Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge is Not Associated with Improvement in Quality of Life.

Journal article Am J Med · October 2025 BACKGROUND: The long-term effects of COVID-19, known as post-acute sequelae of SARS-CoV-2 infection (PASC), impair quality of life (QoL). This secondary analysis of the ACTIV-4c clinical trial evaluates the specific effects of extended thromboprophylaxis w ... Full text Link to item Cite

Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.

Journal article Blood Adv · April 8, 2025 Antithrombotic therapy can prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is, however, associated with an increased risk for major bleeding. This meta-analysis systematically reviewed the evidence regarding the duration of ant ... Full text Link to item Cite

Multimodal quality improvement project on reducing hospital perioperative thromboembolic events (Patient Safety Indicator-12).

Journal article BMJ Open Qual · April 3, 2025 BACKGROUND: Venous thromboembolism (VTE), which includes both pulmonary embolism and deep vein thrombosis, is a common yet significant postoperative complication. Patient Safety Indicator (PSI)-12 was introduced by Centers for Medicare & Medicaid Services ... Full text Link to item Cite

An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

Journal article J Thromb Haemost · February 2025 Antiphospholipid syndrome (APS) diagnosis is dependent on the accurate detection and interpretation of antiphospholipid antibodies (aPL). Lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta2 glycoprotein I antibodies (aβ2GPI) remain t ... Full text Link to item Cite

Genetic and genomic associations in antiphospholipid syndrome: A systematic review.

Journal article Autoimmun Rev · January 31, 2025 BACKGROUND: Numerous genes have been associated with APS in the literature. In recent years, microRNA (miRNA) and long non-coding RNA (lncRNA) have also been shown to modulate the expression of APS-related genes. OBJECTIVE: We performed a systematic review ... Full text Link to item Cite

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.

Journal article Arthritis Care Res (Hoboken) · December 2024 OBJECTIVE: The 2023 American College of Rheumatology/EULAR antiphospholipid syndrome (APS) classification criteria development, which aimed to identify patients with high likelihood of APS for research, employed a four-phase methodology. Phase I and II res ... Full text Link to item Cite

Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical Trials.

Journal article NEJM Evid · November 2024 AbstractIn response to the Covid-19 pandemic, the National Heart, Lung, and Blood Institute launched five multisite clinical trials testing candidate host tissue-directed medical interventions to hasten recovery, improve function, and reduce morbidity and ... Full text Link to item Cite

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal article J Natl Compr Canc Netw · September 2024 The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patient ... Full text Link to item Cite

Magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor in a patient with von Willebrand disease: perioperative optimization for patients with coagulopathies. Illustrative case.

Journal article J Neurosurg Case Lessons · June 10, 2024 BACKGROUND: Essential tremor (ET) is one of the most common movement disorders worldwide. In medically refractory ET, deep brain stimulation (DBS) of the ventral intermediate nucleus of the thalamus is the current standard of care. However, DBS carries an ... Full text Link to item Cite

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.

Journal article N Engl J Med · May 2, 2024 BACKGROUND: Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived products) administered as routine prophylaxis or on ... Full text Link to item Cite

An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county.

Journal article Res Pract Thromb Haemost · May 2024 BACKGROUND: Cancer-associated venous thromboembolism (CA-VTE) represents a major cause of morbidity and mortality in patients with cancer. Despite poor outcomes, there is an ongoing knowledge gap in epidemiologic data related to this association. OBJECTIVE ... Full text Link to item Cite

Evaluation of an automated von Willebrand factor glycoprotein IbM activity assay compared with 3 alternative von Willebrand factor activity assays.

Journal article Res Pract Thromb Haemost · May 2024 BACKGROUND: To overcome deficiencies of the traditional von Willebrand factor (VWF) ristocetin cofactor activity assay (VWF:RCo), several automated assays for VWF platelet-binding activity have been developed. Information on the performance of these assays ... Full text Link to item Cite

High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19.

Journal article Res Pract Thromb Haemost · May 2024 BACKGROUND: The Accelerating COVID-19 Therapeutic Interventions and Vaccines-4c (ACTIV-4c) trial investigated prophylactic apixaban for 30 days following hospitalization for COVID-19. The overall incidence of early postdischarge death or thromboembolism wa ... Full text Link to item Cite

Platelet RNA Biomarker of Ticagrelor-Responsive Genes Is Associated With Platelet Function and Cardiovascular Events.

Journal article Arterioscler Thromb Vasc Biol · February 2024 BACKGROUND: Identifying patients with the optimal risk:benefit for ticagrelor is challenging. The aim was to identify ticagrelor-responsive platelet transcripts as biomarkers of platelet function and cardiovascular risk. METHODS: Healthy volunteers (n=58, ... Full text Link to item Cite

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative.

Journal article J Clin Transl Sci · 2024 This manuscript addresses a critical topic: navigating complexities of conducting clinical trials during a pandemic. Central to this discussion is engaging communities to ensure diverse participation. The manuscript elucidates deliberate strategies employe ... Full text Link to item Cite

2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Journal article Ann Rheum Dis · October 2023 OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international mult ... Full text Link to item Cite

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Journal article Arthritis Rheumatol · October 2023 OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international mult ... Full text Link to item Cite

Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.

Journal article Haemophilia · September 2023 INTRODUCTION: Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AIM: To provide long-term real-world safety and effectiveness data for rpFVIII in the ... Full text Link to item Cite

Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository.

Journal article Arthritis Rheumatol · August 2023 OBJECTIVE: This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid (aPL) antibody-positive patients who ... Full text Link to item Cite

Fluctuation of Anti-Domain 1 and Anti-β2 -Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies.

Journal article Arthritis Rheumatol · June 2023 OBJECTIVE: The present study was undertaken to longitudinally evaluate titers of antibodies against β2 -glycoprotein I (anti-β2 GPI) and domain 1 (anti-D1), to identify predictors of variations in anti-β2 GPI and anti-D1 titers, and to clarify whether anti ... Full text Link to item Cite

Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study.

Journal article Lab Invest · June 2023 Several antiphospholipid antibody (aPL) profiles ("triple" and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardi ... Full text Link to item Cite

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.

Journal article Ann Intern Med · April 2023 BACKGROUND: Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear. OBJECTIVE: To determine whether anticoagulation is superior to placebo in reducing ... Full text Link to item Cite

An antiplatelet response gene expression signature is associated with bleeding.

Journal article Cardiovasc Res · March 31, 2023 AIMS: Gene expression biosignatures may hold promise to individualize antiplatelet therapy in conjunction with current guidelines and risk scores. The Aspirin Response Signature (ARS) score is comprised of a weighted sum of correlated, pro-thrombotic gene ... Full text Link to item Cite

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.

Journal article BMJ · February 27, 2023 Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid binding proteins. The result is an increased risk of thrombotic events, pregnancy morbidity ... Full text Link to item Cite

Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.

Journal article J Thromb Haemost · December 2022 Patients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone ... Full text Link to item Cite

Introduction to a review series on COVID-19 and the hematologist.

Journal article Blood · July 21, 2022 Since the COVID-19 pandemic began over 2 years ago, its global impact has been enormous. Our growing understanding of the pathophysiology of this disease has particular links to hematology. Introduced by Ortel and Berliner, this Review Series provides up-t ... Full text Link to item Cite

Racial differences in venous thromboembolism: A surveillance program in Durham County, North Carolina.

Journal article Res Pract Thromb Haemost · July 2022 BACKGROUND: Venous thromboembolism (VTE) affects approximately 1-2 individuals per 1000 annually and is associated with an increased risk for pulmonary hypertension, postthrombotic syndrome, and recurrent VTE. OBJECTIVE: To determine risk factors, incidenc ... Full text Link to item Cite

Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery.

Journal article J Vasc Surg Venous Lymphat Disord · May 2022 BACKGROUND: Venous thromboembolism (VTE) is a well-known complication associated with surgical procedures. The implementation of thromboprophylaxis in this population has become a vital aspect of perioperative care to decrease VTE-associated morbidity and ... Full text Link to item Cite

Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function.

Journal article Br J Clin Pharmacol · May 2022 Aspirin has known effects beyond inhibiting platelet cyclooxygenase-1 (COX-1) that have been incompletely characterized. Transcriptomics can comprehensively characterize the on- and off-target effects of medications. We used a systems pharmacogenomics appr ... Full text Link to item Cite

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.

Journal article Ann Intern Med · April 2022 BACKGROUND: Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. It presents similarly to spontaneous heparin-induced thrombocytopenia. Twelve cases of cerebra ... Full text Link to item Cite

New methods facilitated the process of prioritizing questions and health outcomes in guideline development.

Journal article J Clin Epidemiol · March 2022 BACKGROUND: Health guideline development requires sequential prioritization of the guideline topic, questions, and health outcomes. In this paper we report on new approaches for prioritizing questions and outcomes in guidelines. METHODS: Ten guideline pane ... Full text Link to item Cite

Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.

Journal article J Thromb Thrombolysis · January 2022 Limited data exists regarding the clinical outcomes of andexanet alfa and four factor prothrombin complex concentrate (4F-PCC) for reversal of apixaban or rivaroxaban in the setting of intracranial hemorrhage (ICH). The objective of this study was to evalu ... Full text Link to item Cite

Exploring the Applicability of Using Natural Language Processing to Support Nationwide Venous Thromboembolism Surveillance: Model Evaluation Study

Journal article Jmir Bioinformatics and Biotechnology · January 1, 2022 Background: Venous thromboembolism (VTE) is a preventable, common vascular disease that has been estimated to affect up to 900,000 people per year. It has been associated with risk factors such as recent surgery, cancer, and hospitalization. VTE surveillan ... Full text Cite

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines.

Journal article Blood Adv · November 23, 2021 Trustworthy health guidelines should provide recommendations, document the development process, and highlight implementation information. Our objective was to develop a guideline manuscript template to help authors write a complete and useful report. The M ... Full text Link to item Cite

Successful Management of Catastrophic Thrombotic Storm in a Young Boy: A Case Report From Northern India.

Journal article J Pediatr Hematol Oncol · November 1, 2021 Thrombotic storm is a rare clinical entity characterized by acute to subacute thrombosis developing at multiple sites over a few days to a few weeks. An 11-year-old boy presented with headache and facial nerve palsy. He was found to have cortical sinus ven ... Full text Link to item Cite

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal article J Natl Compr Canc Netw · October 15, 2021 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromb ... Full text Link to item Cite

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.

Journal article Arthritis Care Res (Hoboken) · October 2021 OBJECTIVE: An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients wit ... Full text Link to item Cite

Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines.

Journal article J Clin Epidemiol · October 2021 OBJECTIVE: Stakeholders involved in developing recommendations need to have a common understanding of health outcomes and the perspective of affected individuals. In this paper we report on the development and application of health outcome descriptors (HOD ... Full text Link to item Cite

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don't Know.

Journal article Blood · June 1, 2021 Development of vaccines to fight COVID19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platele ... Full text Link to item Cite

Thromboprophylaxis for orthopedic surgery; An updated meta-analysis.

Journal article Thromb Res · March 2021 BACKGROUND: Venous thromboembolism (VTE) is a serious complication of orthopedic surgery. Low molecular weight heparin (LMWH) has been the standard of care for thromboprophylaxis in this population. However, direct oral anticoagulants (DOACs) are increasin ... Full text Link to item Cite

Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.

Journal article J Thromb Thrombolysis · February 2021 Platelet gene polymorphisms are associated with variable on-treatment platelet reactivity and vary by race. Whether differences in platelet reactivity and aspirin or ticagrelor exist between African-American and European-Americans remains poorly understood ... Full text Link to item Cite

Meta-analysis fever in the wake of CARAVAGGIO.

Journal article Thromb Res · December 2020 Full text Link to item Cite

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.

Journal article Thromb Res · December 2020 • COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation. ... Full text Link to item Cite

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.

Journal article J Thromb Haemost · November 2020 This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as well as interpretation of results for clinicians. The main changes in how to test for LA compared with the International Society on Thrombosis and Haemostasis Scientifi ... Full text Link to item Cite

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Journal article Blood Adv · October 13, 2020 BACKGROUND: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. OBJECTIVE: These e ... Full text Link to item Cite

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Journal article Lupus · October 2020 Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task ... Full text Link to item Cite

Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry.

Journal article Lupus · October 2020 OBJECTIVE: This study aimed to use cluster analysis (CA) to identify different clinical phenotypes among antiphospholipid antibodies (aPL)-positive patients. METHODS: The Alliance for Clinical Trials and International Networking (APS ACTION) Registry inclu ... Full text Link to item Cite

Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.

Journal article J Thromb Haemost · September 2020 BACKGROUND: Patients with antiphospholipid antibodies (aPL) and thromboembolism (TE) are at risk for recurrent TE. Few studies, however, distinguish patients based on the initial event. OBJECTIVES: We performed a systematic review and meta-analysis to inve ... Full text Link to item Cite

ISTH DIC subcommittee communication on anticoagulation in COVID-19.

Journal article J Thromb Haemost · September 2020 Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate ty ... Full text Link to item Cite

Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.

Journal article Radiat Res · August 1, 2020 Thrombocytopenia (TCP) may cause severe and life-threatening bleeding. While this may be prevented by platelet transfusions, transfusions are associated with potential complications, do not always work (platelet refractory) and are not always available. Th ... Full text Link to item Cite

Influence of Sex on Platelet Reactivity in Response to Aspirin.

Journal article J Am Heart Assoc · July 21, 2020 Background There are sex differences in the efficacy and safety of aspirin for the prevention of myocardial infarction and stroke. Whether this is explained by underlying differences in platelet reactivity and aspirin response remains poorly understood. Me ... Full text Link to item Cite

Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings.

Journal article J Pharm Technol · June 2020 Objective: To report the utilization of emicizumab in a patient with severe hemophilia A with inducible inhibitors and the reduction of drug costs related to decreased on-demand recombinant factor VIIa use. Case Summary: A 65-year-old African American man ... Full text Link to item Cite

Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.

Journal article Blood Adv · May 26, 2020 BACKGROUND: Methods for the development of clinical guidelines have advanced dramatically over the past 2 decades to strive for trustworthiness, transparency, user-friendliness, and rigor. The American Society of Hematology (ASH) guidelines on venous throm ... Full text Link to item Cite

Physical Activity in the Hospital: Documentation and Influence on Venous Thromboembolism Prophylaxis.

Journal article J Aging Phys Act · April 24, 2020 This study describes the availability of physical activity information in the electronic health record, explores how electronic health record documentation correlates with accelerometer-derived physical activity data, and examines whether measured physical ... Full text Link to item Cite

Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.

Journal article Blood Adv · February 11, 2020 Increasing evidence supports the safety and effectiveness of managing low-risk deep vein thrombosis (DVT) or pulmonary embolism (PE) in outpatient settings. We performed a systematic review to assess safety and effectiveness of managing patients with DVT o ... Full text Link to item Cite

Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.

Journal article Vox Sang · May 2019 BACKGROUND/OBJECTIVES: Prothrombin complex concentrates (PCC) are increasingly administered off-label in the United States to treat bleeding in cardiovascular surgical patients and carry the potential risk for acquired thromboembolic side-effects after sur ... Full text Open Access Link to item Cite

Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches.

Journal article Appl Clin Inform · May 2019 BACKGROUND: Systematic surveillance for venous thromboembolism (VTE) in the United States has been recommended by several organizations. Despite adoption of electronic medical records (EMRs) by most health care providers and facilities, however, systematic ... Full text Link to item Cite

Bad weed: synthetic cannabinoid-associated coagulopathy.

Journal article Blood · February 28, 2019 Recent multistate outbreaks of coagulopathy caused by brodifacoum-tainted synthetic cannabinoids or "fake weed" highlight the public health impact of long-acting anticoagulant rodenticides (LAARs). Patients presenting with this syndrome have had recent exp ... Full text Link to item Cite

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.

Journal article J Natl Compr Canc Netw · November 2018 Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline str ... Full text Link to item Cite

Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study.

Journal article J Clin Apher · August 2018 INTRODUCTION: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation. METHODS: In a retrospective study of patients who underwent cardiac transplantation at Duke University Medical ... Full text Open Access Link to item Cite

Extended anticoagulation for unprovoked venous thromboembolism.

Journal article Res Pract Thromb Haemost · July 2018 After completing anticoagulation therapy for acute venous thromboembolism (VTE), patients with unprovoked VTE are at increased risk of recurrent thrombotic events. Recent studies suggest a risk of nearly 10% in the first year after stopping anticoagulants ... Full text Link to item Cite

Automated versus Manual Data Extraction of the Padua Prediction Score for Venous Thromboembolism Risk in Hospitalized Older Adults.

Journal article Appl Clin Inform · July 2018 OBJECTIVE: Venous thromboembolism (VTE) prophylaxis is an important consideration for hospitalized older adults, and the Padua Prediction Score (PPS) is a risk prediction tool used to prioritize patient selection. We developed an automated PPS (APPS) algor ... Full text Link to item Cite

Bleeding and thrombotic complications of pediatric liver transplant.

Journal article Pediatr Blood Cancer · May 2018 BACKGROUND: Pediatric patients undergoing liver transplant are at significant risk for bleeding and thrombotic complications due to the complex nature of rebalanced hemostasis in patients with liver disease. METHODS/OBJECTIVES: We reviewed records of 92 pe ... Full text Link to item Cite

Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis.

Journal article J Thromb Haemost · February 2018 UNLABELLED: Essentials We developed a prediction model for postthrombotic syndrome (PTS) after deep vein thrombosis (DVT). High risk predictors were iliac vein DVT, BMI>35 and moderate-severe Villalta category. Patients with a score ≥4 had an odds ratio of ... Full text Link to item Cite

Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.

Journal article Am Heart J · January 2018 BACKGROUND: The use of low-molecular weight heparin bridge therapy during warfarin interruption for elective surgery/procedures increases bleeding. Other predictors of bleeding in this setting are not well described. METHODS: BRIDGE was a randomized, doubl ... Full text Link to item Cite

Variants in chondroitin sulfate metabolism genes in thrombotic storm.

Journal article Thromb Res · January 2018 INTRODUCTION: Thrombotic storm (TS) presents as a severe, acute thrombotic phenotype, characterized by multiple clotting events and frequently affecting younger adults. Understanding the extensive hypercoagulation of an extreme phenotype as TS will also pr ... Full text Link to item Cite

Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.

Journal article Am J Hematol · August 2017 BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder usually prompting treatment with non-heparin anticoagulants. The benefits and risks of such treatments have not been fully assessed. METHODS: We analyzed data for 442 patients havi ... Full text Link to item Cite

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.

Journal article J Am Heart Assoc · July 11, 2017 BACKGROUND: Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and s ... Full text Link to item Cite

Heparin-induced thrombocytopenia.

Journal article Blood · May 25, 2017 Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular FcγRIIA on platelets and monocytes ... Full text Link to item Cite

Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients.

Journal article Eur J Prev Cardiol · April 2017 Aims Mental stress-induced myocardial ischemia (MSIMI) occurs in up to 70% of patients with clinically stable ischemic heart disease and is associated with increased risk of adverse prognosis. We aimed to examine the prognostic value of indices of MSIMI an ... Full text Link to item Cite

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.

Journal article BMJ · March 17, 2017 Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30; or Older age, ≥65 years), which states that women with none or one of the criteria can safe ... Full text Link to item Cite

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.

Journal article J Am Coll Cardiol · February 21, 2017 Periprocedural management of anticoagulation is a common clinical conundrum that involves a multidisciplinary team, cuts across many specialties, and varies greatly between institutions in the way it is practiced. Nowhere is this more evident than in the m ... Full text Link to item Cite

Associations between positive emotional well-being and stress-induced myocardial ischemia: Well-being scores predict exercise-induced ischemia.

Journal article J Psychosom Res · February 2017 OBJECTIVE: Depressive symptoms have been associated with myocardial ischemia induced by mental (MSIMI) and exercise (ESIMI) stress in clinically stable ischemic heart disease (IHD) patients, but the association between positive emotions and inducible ische ... Full text Link to item Cite

The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery.

Journal article J Thromb Haemost · January 2017 UNLABELLED: Essentials We evaluated antibody status, thromboembolism and survival after cardiac surgery. Positive antibody tests are common - over 50% are seropositive at 30 days. Seropositivity did not increase thromboembolism or impair survival after car ... Full text Link to item Cite

Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial.

Journal article Can J Anaesth · November 2016 PURPOSE: Postoperative cognitive dysfunction (POCD) occurs frequently after cardiac surgery. The pathophysiology of POCD remains elusive, but previous work showed that intravenous lidocaine may be protective against POCD, possibly by modulating cerebral in ... Full text Link to item Cite

A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation.

Journal article Curr Cardiol Rep · October 2016 In patients with atrial fibrillation (AF), oral anticoagulation is used to prevent stroke and systemic embolism. In a common clinical scenario, AF patients frequently undergo invasive procedures requiring temporary interruption of oral anticoagulation, the ... Full text Link to item Cite

Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.

Journal article EBioMedicine · September 2016 Aspirin prevents cardiovascular disease and colon cancer; however aspirin's inhibition of platelet COX-1 only partially explains its diverse effects. We previously identified an aspirin response signature (ARS) in blood consisting of 62 co-expressed transc ... Full text Link to item Cite

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Journal article N Engl J Med · August 11, 2016 BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assign ... Full text Link to item Cite

Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review.

Journal article J Arthroplasty · February 2016 BACKGROUND: Thromboprophylaxis regimens include pharmacologic and mechanical options such as intermittent pneumatic compression devices (IPCDs). There are a wide variety of IPCDs available, but it is uncertain if they vary in effectiveness or ease of use. ... Full text Link to item Cite

Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis.

Journal article J Vasc Surg Venous Lymphat Disord · October 2015 OBJECTIVE: Inflammation may play a role in pathogenesis of venous thromboembolism, but the nature of this relationship is not yet understood. The objective of this study was to assess whether inflammation marker levels measured at diagnosis of deep venous ... Full text Link to item Cite

How I treat catastrophic thrombotic syndromes.

Journal article Blood · September 10, 2015 Catastrophic thrombotic syndromes are characterized by rapid onset of multiple thromboembolic occlusions affecting diverse vascular beds. Patients may have multiple events on presentation, or develop them rapidly over days to weeks. Several disorders can p ... Full text Link to item Cite

Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism.

Journal article Thromb Res · September 2015 INTRODUCTION: The objective of this study was to examine the differences in commonly associated characteristics and risk factors of venous thromboembolism (VTE) between patients with and without cancer in a VTE population. MATERIALS AND METHODS: Uniform da ... Full text Link to item Cite

Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.

Journal article J Natl Compr Canc Netw · September 2015 The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common ... Full text Link to item Cite

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Journal article N Engl J Med · August 27, 2015 BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bri ... Full text Link to item Cite

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Journal article J Thromb Haemost · June 2015 BACKGROUND: Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes afte ... Full text Link to item Cite

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Journal article J Thromb Haemost · June 2015 BACKGROUND: Treatment of venous thromboembolism (VTE) in patients with cancer has a high rate of recurrence and bleeding complications. Guidelines recommend low-molecular-weight heparin (LMWH) for at least 3-6 months and possibly indefinitely for patients ... Full text Link to item Cite

Effects of red-cell storage duration on patients undergoing cardiac surgery.

Journal article N Engl J Med · April 9, 2015 BACKGROUND: Some observational studies have reported that transfusion of red-cell units that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse events. Patients undergoing cardiac surgery may be especially vulnerabl ... Full text Link to item Cite

Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.

Journal article Thromb Res · April 2015 INTRODUCTION: Recurrent venous thromboembolism (VTE) occurs infrequently following a provoked event but occurs in up to 30% of individuals following an initial unprovoked event. There is limited understanding of the biological mechanisms that predispose pa ... Full text Link to item Cite

Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.

Journal article Am Heart J · April 2015 BACKGROUND: Mental stress-induced myocardial ischemia (MSIMI) is common in patients with ischemic heart disease (IHD) and associated with a poorer cardiovascular prognosis. Platelet hyperactivity is an important factor in acute coronary syndrome. This stud ... Full text Open Access Link to item Cite

Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study

Journal article American Heart Journal · April 1, 2015 Background Mental stress-induced myocardial ischemia (MSIMI) is common in patients with ischemic heart disease (IHD) and associated with a poorer cardiovascular prognosis. Platelet hyperactivity is an important factor in acute coronary syndrome. This study ... Full text Cite

Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome.

Journal article J Thromb Haemost · March 2015 BACKGROUND: Post-thrombotic syndrome (PTS) is a frequent chronic complication of deep vein thrombosis (DVT). OBJECTIVE: In the BioSOX study, we investigated whether inflammation markers predict the risk of PTS after DVT. METHODS: We measured C-reactive pro ... Full text Link to item Cite

Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Journal article Thromb Res · January 2015 OBJECTIVE: This study assessed the risk of venous thromboembolism (VTE) among privately insured adults in the U.S. with one or more of the following autoimmune diseases: autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP), rheumatoid ... Full text Link to item Cite

Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?

Journal article Annu Rev Med · 2015 The target-specific oral anticoagulants are a class of agents that inhibit factor Xa or thrombin. They are effective and safe compared to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment ... Full text Link to item Cite

Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial.

Journal article Thromb Haemost · December 2014 Acute deep venous thrombosis (DVT) causes leg pain. Elastic compression stockings (ECS) have potential to relieve DVT-related leg pain by diminishing the diameter of distended veins and increasing venous blood flow. It was our objective to determine whethe ... Full text Link to item Cite

Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.

Journal article J Am Coll Cardiol · October 21, 2014 BACKGROUND: Although emotional stress is associated with ischemic heart disease (IHD) and related clinical events, sex-specific differences in the psychobiological response to mental stress have not been clearly identified. OBJECTIVES: We aimed to study th ... Full text Link to item Cite

Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Journal article J Thromb Thrombolysis · October 2014 Previous research has suggested autoimmune diseases are risk factors for developing venous thromboembolism (VTE). We assessed whether having diagnoses of selected autoimmune diseases associated with antiphospholipid antibodies--autoimmune hemolytic anemia ... Full text Link to item Cite

The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

Journal article J Thromb Thrombolysis · October 2014 The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin gen ... Full text Link to item Cite

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Journal article Autoimmun Rev · September 2014 Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in the presence of at least one of the two major clinical manifestations ... Full text Link to item Cite

Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability.

Journal article CPT Pharmacometrics Syst Pharmacol · July 16, 2014 While aspirin is generally effective for prevention of cardiovascular disease, considerable variation in drug response exists, resulting in some individuals displaying high on-treatment platelet reactivity. We used pharmacometabolomics to define pathways i ... Full text Link to item Cite

14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

Journal article Autoimmun Rev · June 2014 Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The primary objective of the APS Treatment Trends Task Force, created as part of the ... Full text Link to item Cite

Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.

Journal article Thromb Res · April 2014 Fondaparinux is an antithrombin-dependent factor Xa inhibitor that is used for thromboprophylaxis of patients undergoing hip fracture surgery, hip or knee replacement, or abdominal surgery. It is cleared by the kidney and should be used with caution in pat ... Full text Link to item Cite

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.

Journal article Lancet · March 8, 2014 BACKGROUND: Post-thrombotic syndrome (PTS) is a common and burdensome complication of deep venous thrombosis (DVT). Previous trials suggesting benefit of elastic compression stockings (ECS) to prevent PTS were small, single-centre studies without placebo c ... Full text Link to item Cite

Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome.

Journal article Thromb Res · January 2014 INTRODUCTION: Black women have an increased risk of adverse pregnancy outcomes and the characteristics of thrombotic risk factors in this population are unknown. The objective of this study was to examine the racial differences in thrombotic risk factors a ... Full text Link to item Cite

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Journal article N Engl J Med · December 12, 2013 BACKGROUND: The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. METHODS: We randomly assigned 1015 patients to receive doses ... Full text Link to item Cite

Venous thromboembolic disease.

Journal article J Natl Compr Canc Netw · November 2013 Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complica ... Full text Link to item Cite

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.

Journal article J Am Coll Cardiol · October 1, 2013 OBJECTIVES: The aim of this study was to develop ribonucleic acid (RNA) profiles that could serve as novel biomarkers for the response to aspirin. BACKGROUND: Aspirin reduces death and myocardial infarction (MI), suggesting that aspirin interacts with biol ... Full text Link to item Cite

Antithrombotic therapy and invasive procedures.

Journal article N Engl J Med · September 12, 2013 Full text Link to item Cite

Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.

Journal article Ann Intern Med · August 20, 2013 BACKGROUND: Pharmacologic thromboprophylaxis reduces the risk for venous thromboembolism after total hip replacement (THR) or total knee replacement (TKR). New oral anticoagulants (NOACs), including direct thrombin inhibitors and factor Xa inhibitors, are ... Full text Link to item Cite

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.

Journal article JAMA · May 22, 2013 IMPORTANCE: Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress-induced myocardial ischemia (MSIMI) have not been well studied. OBJEC ... Full text Link to item Cite

Randomized trial of physician alerts for thromboprophylaxis after discharge.

Journal article Am J Med · May 2013 BACKGROUND: Many hospitalized Medical Service patients are at risk for venous thromboembolism in the months after discharge. We conducted a multicenter randomized controlled trial to test whether a hospital staff member's thromboprophylaxis alert to an Att ... Full text Link to item Cite

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Journal article Blood · April 11, 2013 Protamine is routinely used to reverse heparin anticoagulation during cardiopulmonary bypass (CPB). Heparin interacts with protamine to form ultralarge complexes that are immunogenic in mice. We hypothesized that patients exposed to protamine and heparin d ... Full text Link to item Cite

Characteristics of abdominal vein thrombosis in children and adults.

Journal article Thromb Haemost · April 2013 The demographic and clinical characteristics of adults and children with lower extremity deep-vein thrombosis and/or pulmonary embolism (LE DVT/PE) may differ from those with abdominal vein thrombosis (abdominal VT). Abdominal VT can be a presenting sign o ... Full text Open Access Link to item Cite

Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis.

Journal article Hosp Pract (1995) · April 2013 Clinicians are aware of the importance of thromboprophylaxis, and that the application of measures to prevent venous thromboembolism (VTE) occurrence in hospitalized patients must be improved. To enhance clinician execution of appropriate steps to reduce t ... Full text Link to item Cite

Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease.

Journal article J Am Coll Cardiol · February 19, 2013 OBJECTIVES: The goal of this study was to evaluate the prevalence and clinical characteristics of mental stress-induced myocardial ischemia. BACKGROUND: Mental stress-induced myocardial ischemia is prevalent and a risk factor for poor prognosis in patients ... Full text Link to item Cite

Anticoagulation in the Perioperative Period

Journal article · January 1, 2013 Full text Cite

Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

Journal article Thromb Haemost · January 2013 The mechanism underlying a hyperreactive platelet phenotype remains unknown. Since serotonin has been shown to influence platelet biology and atherothrombosis, we sought to investigate the association of platelet serotonin transporter number, binding affin ... Full text Link to item Cite

Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease.

Journal article Psychosom Med · 2013 OBJECTIVES: The aim of this study was to examine the associations between depressive symptoms and mental stress-induced myocardial ischemia (MSIMI) in patients with coronary heart disease (CHD). METHODS: Adult patients with documented CHD were recruited fo ... Full text Link to item Cite

Perioperative management of patients on chronic antithrombotic therapy.

Journal article Blood · December 6, 2012 Perioperative management of antithrombotic therapy is a situation that occurs frequently and requires consideration of the patient, the procedure, and an expanding array of anticoagulant and antiplatelet agents. Preoperative assessment must address each pa ... Full text Link to item Cite

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.

Journal article Ann Intern Med · December 4, 2012 BACKGROUND: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs) and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of atrial fibrillation (AF) and venous thromboembolism (VTE). PURPOSE: To compa ... Full text Link to item Cite

Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.

Journal article Thromb Haemost · December 2012 Plasma proteins mediate thrombogenesis, inflammation, endocardial injury and structural remodelling in atrial fibrillation (AF). We hypothesised that anti-coagulation with rivaroxaban, a direct factor Xa inhibitor, would differentially modulate biologicall ... Full text Link to item Cite

Clinical causes and treatment of the thrombotic storm.

Journal article Expert Rev Hematol · December 2012 Thrombotic storm represents an extreme prothrombotic phenotype, characterized by multiple thrombotic events affecting diverse vascular beds occurring over a brief period of time. Thrombotic events involve venous and arterial circulation, including unusual ... Full text Link to item Cite

Clinical causes and treatment of the thrombotic storm.

Journal article Expert review of hematology · December 1, 2012 Thrombotic storm represents an extreme prothrombotic phenotype, characterized by multiple thrombotic events affecting diverse vascular beds occurring over a brief period of time. Thrombotic events involve venous and arterial circulation, including unusual ... Cite

Characterization of the hypercoagulable state in patients with sickle cell disease.

Journal article Thromb Res · November 2012 BACKGROUND: The pathophysiology of sickle cell disease (SCD) is complex, with increasing evidence of a pronounced prothrombotic state. OBJECTIVE: We investigated thrombin generation in SCD utilizing calibrated automated thrombography (CAT) and D-dimer, wit ... Full text Link to item Cite

Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).

Journal article Semin Thromb Hemost · November 2012 Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this ... Full text Link to item Cite

To bridge or not to bridge: these are the questions.

Journal article J Thromb Thrombolysis · July 2012 Full text Link to item Cite

Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Journal article Am J Hematol · May 2012 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies. Diagnostic tests for the detection of antiphospholipi ... Full text Link to item Cite

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Journal article Am J Hematol · May 2012 The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over warfarin which include no need for laboratory monitoring, less drug-drug interactions and less food-drug interactions. However, there is no established antidote for patie ... Full text Link to item Cite

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Journal article J Thromb Thrombolysis · April 2012 To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics. NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. Although a varie ... Full text Link to item Cite

Laboratory diagnosis of the lupus anticoagulant.

Journal article Curr Rheumatol Rep · February 2012 Lupus anticoagulants are autoantibodies that are associated with an increased risk of thromboembolic events and adverse pregnancy outcomes. They are identified by a systematic, laboratory-based approach that includes the following steps: 1) prolongation of ... Full text Link to item Cite

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Journal article Chest · February 2012 BACKGROUND: VTE is a serious, but decreasing complication following major orthopedic surgery. This guideline focuses on optimal prophylaxis to reduce postoperative pulmonary embolism and DVT. METHODS: The methods of this guideline follow those described in ... Full text Link to item Cite

Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.

Journal article Am Heart J · January 2012 BACKGROUND: Mental stress-induced myocardial ischemia (MSIMI) is common in patients with clinically stable coronary heart disease (CHD) and is associated with poor outcomes. Depression is a risk factor of MSIMI. The REMIT trial investigates whether selecti ... Full text Link to item Cite

Perioperative management of patients on chronic antithrombotic therapy.

Journal article Hematology Am Soc Hematol Educ Program · 2012 Perioperative management of antithrombotic therapy is a situation that occurs frequently and requires consideration of the patient, the procedure, and an expanding array of anticoagulant and antiplatelet agents. Preoperative assessment must address each pa ... Full text Link to item Cite

Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism.

Journal article Thromb Res · December 2011 INTRODUCTION: Venous thromboembolism may recur in up to 30% of patients with a spontaneous venous thromboembolism after a standard course of anticoagulation. Identification of patients at risk for recurrent venous thromboembolism would facilitate decisions ... Full text Link to item Cite

Venous thromboembolic disease.

Journal article J Natl Compr Canc Netw · July 1, 2011 Full text Link to item Cite

Heparin-induced thrombocytopenia in cancer.

Journal article J Natl Compr Canc Netw · July 1, 2011 Heparin-induced thrombocytopenia is a common and clinically important drug-induced complication that can cause life- and limbthreatening thrombosis. Epidemiologically, the disease has been studied in many different clinical settings, but little is known ab ... Full text Link to item Cite

Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies.

Journal article Blood Coagul Fibrinolysis · June 2011 Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin that must be identified quickly to determine appropriate anticoagulant therapy strategies. The most common antibodies involved in HIT are directed against platelet fac ... Full text Link to item Cite

Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group.

Journal article Am J Med · April 2011 Physicians periodically encounter patients with an extraordinarily accelerated course of hypercoagulability who develop thromboses in multiple organ systems over days to weeks. Such patients may harbor underlying hypercoagulable clinical conditions, but th ... Full text Link to item Cite

Antiphospholipid Syndrome Clinical Research Task Force report.

Journal article Lupus · February 2011 The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of six Task Forces developed by the 13(th) International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: a) evaluating the limitations ... Full text Link to item Cite

'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.

Journal article Lupus · February 2011 Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-β(2)gly ... Full text Link to item Cite

Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus.

Journal article Clin Appl Thromb Hemost · February 2011 BACKGROUND: The use of bovine thrombin has been an effective approach to aiding hemostasis during surgery for over 60 years. Its use has a reported association with the development of antibodies to coagulation factors with limited evidence to the clinical ... Full text Link to item Cite

Heparin modifies the immunogenicity of positively charged proteins.

Journal article Blood · December 23, 2010 The immune response in heparin-induced thrombocytopenia is initiated by and directed to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H). We have previously shown that PF4:H multimolecular complexes assemble through electrostatic i ... Full text Link to item Cite

The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.

Journal article J Thromb Haemost · December 2010 BACKGROUND: The diagnosis of heparin-induced thrombocytopenia (HIT) is challenging. Over-diagnosis and over-treatment are common. OBJECTIVES: To develop a pre-test clinical scoring model for HIT based on broad expert opinion that may be useful in guiding c ... Full text Link to item Cite

Assays for measuring rivaroxaban: their suitability and limitations.

Journal article Ther Drug Monit · December 2010 Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development and are already available for clinical use in some countries. Although these agen ... Full text Link to item Cite

Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Journal article Blood · September 9, 2010 The diagnosis of heparin-induced thrombocytopenia (HIT) requires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immunosorbent assay. Addition of excess heparin to the sample decreases the optical density by 50% o ... Full text Link to item Cite

The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.

Journal article Thromb Res · September 2010 UNLABELLED: Atherosclerosis develops in an environment of endothelial injury and inflammation. Circulating endothelial progenitor cells (EPCs) are required for vascular repair and restoration of normal endothelial function. We tested the hypothesis that th ... Full text Link to item Cite

Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study.

Journal article Am J Hematol · July 2010 When compared with Whites, Black-Americans may have a 40% higher incidence venous thromboembolism (VTE) incidence. However, whether other VTE characteristics and risk factors vary by race is uncertain. To compare demographic and baseline characteristics am ... Full text Link to item Cite

Nephrology

Journal article · May 5, 2010 The objective of this chapter is to highlight problems of hemostasis and thrombosis in regards to renal disease. The topics included are bleeding in renal disease, renal vein thrombosis, nephrotic syndrome/hypercoagulability, graft loss due to thromobosis/ ... Full text Cite

Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall.

Journal article Psychosom Med · May 2010 OBJECTIVE: To examine the effects of depressive symptoms and hostility on changes in C-reactive protein (CRP) and interleukin (IL)-6 in response to an acute laboratory stressor. Depressive symptoms moderate the effect of trait hostility on circulating leve ... Full text Link to item Cite

Venous thromboembolism: a public health concern.

Journal article Am J Prev Med · April 2010 Venous thromboembolism (VTE), defined as deep vein thrombosis, pulmonary embolism, or both, affects an estimated 300,000-600,000 individuals in the U.S. each year, causing considerable morbidity and mortality. It is a disorder that can occur in all races a ... Full text Link to item Cite

Dose of prophylactic platelet transfusions and prevention of hemorrhage.

Journal article N Engl J Med · February 18, 2010 BACKGROUND: We conducted a trial of prophylactic platelet transfusions to evaluate the effect of platelet dose on bleeding in patients with hypoproliferative thrombocytopenia. METHODS: We randomly assigned hospitalized patients undergoing hematopoietic ste ... Full text Link to item Cite

Acquired thrombotic risk factors in the critical care setting.

Journal article Crit Care Med · February 2010 Acquired thrombotic risk factors include a variety of noninherited clinical conditions that can predispose an individual to an increased risk for venous thromboembolism. For patients in a critical care setting, certain acquired risk factors represent chron ... Full text Link to item Cite

Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.

Journal article Anesth Analg · January 1, 2010 BACKGROUND: Heparin-induced thrombocytopenia (HIT) complicates the management of patients presenting for cardiac surgery, because high-dose heparin anticoagulation for cardiopulmonary bypass is contraindicated in these patients. Alternative anticoagulants ... Full text Link to item Cite

Heparin-induced thrombocytopenia.

Journal article Annu Rev Med · 2010 Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytop ... Full text Link to item Cite

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Journal article J Clin Oncol · October 10, 2009 Changes in the hemostatic system and chronic hemostatic activation are frequently observed in patients with cancer, even in the absence of venous thromboembolism (VTE). VTE is a leading cause of death among patients with cancer and contributes to long-term ... Full text Link to item Cite

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Journal article J Thromb Haemost · October 2009 One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspec ... Full text Link to item Cite

Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients.

Journal article J Thromb Thrombolysis · August 2009 Patients who develop thrombocytopenia and heparin-dependent platelet factor 4 antibodies while on or shortly after receiving a heparin product are often considered for alternative anticoagulation to minimize the occurrence of life and limb-threatening even ... Full text Link to item Cite

Recent developments in topical thrombins.

Journal article Thromb Haemost · July 2009 Managing blood loss is part of the surgeon's responsibility during surgical procedures, and a variety of therapeutic strategies are available to help accomplish this. Topical haemostatic agents are among the agents used to control surgical bleeding and loc ... Full text Link to item Cite

Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.

Journal article Am J Hematol · June 2009 Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), the most c ... Full text Link to item Cite

Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).

Journal article Kidney Int Suppl · February 2009 Thrombotic thrombocytopenic purpura (TTP) is a fulminant disease characterized by platelet aggregates, thrombocytopenia, renal insufficiency, neurologic changes, and mechanical injury to erythrocytes. Most idiopathic cases of TTP are characterized by a def ... Full text Link to item Cite

ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?

Journal article Hematology Am Soc Hematol Educ Program · 2009 You are asked to consult on a 76-year-old man admitted to the hospital with pneumonia and thrombocytopenia. Ten days before the current admission, he had undergone surgery to repair a small bowel obstruction. A preoperative platelet count had been normal. ... Full text Link to item Cite

Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.

Journal article Hematology Am Soc Hematol Educ Program · 2009 Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder caused by the development of antibodies to platelet factor 4 (PF4) and heparin. The thrombocytopenia is typically moderate, with a median platelet count nadir of approximately 50 to 60 x ... Full text Link to item Cite

Molecular testing for coagulopathies

Journal article · December 1, 2008 Sudden and severe loss of blood can lead to shock and death. When blood vessels are damaged, Hemostasis (clot formation) will arrest bleeding. This proces is divided into primary and secondary hemostasis. © 2008 Humana Press. ... Full text Cite

Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.

Journal article Thromb Haemost · October 2008 Laboratory testing for heparin-induced thrombocytopenia (HIT) includes the highly sensitive, though less specific, heparin/platelet factor 4 (PF4) ELISA. A confirmatory test with excess heparin is routinely performed on positive ELISA results to improve te ... Full text Link to item Cite

Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation.

Journal article J Thromb Thrombolysis · August 2008 BACKGROUND AND OBJECTIVE: Internet-based disease management programs have the potential to improve patient care. The objective of this study was to determine whether an interactive, internet-based system enabling supervised, patient self-management of oral ... Full text Link to item Cite

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Journal article Haemophilia · March 2008 von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disproportionate ... Full text Link to item Cite

Thrombophilias: when should we test and how does it help?

Journal article Semin Respir Crit Care Med · February 2008 Venous thromboembolism can be a life-threatening event, occurring in ~1 in 1000 adults annually. An underlying cause for thrombosis can now be identified in up to 80% of cases, including both inherited and acquired causes of thrombophilia. In fact, it is o ... Full text Link to item Cite

Thrombophilia screening in asymptomatic children.

Journal article Thromb Res · 2008 Children with a family history of thrombophilia and/or thrombosis are often referred to pediatric thrombosis centers for evaluation. This article reviews the risks and benefits of thrombophilia testing in this unique population. The article also reviews an ... Full text Link to item Cite

Prevention and treatment of deep venous thrombosis.

Journal article Vascular · 2008 Postoperative venous thromboembolism (VTE) is a common cause of preventable patient morbidity and mortality. Hospitalized patients have multiple risk factors for VTE, which can exert a cumulative effect on the individual patient. Although effective thrombo ... Link to item Cite

Evolution of adverse changes in stored RBCs.

Journal article Proc Natl Acad Sci U S A · October 23, 2007 Recent studies have underscored questions about the balance of risk and benefit of RBC transfusion. A better understanding of the nature and timing of molecular and functional changes in stored RBCs may provide strategies to improve the balance of benefit ... Full text Link to item Cite

Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.

Journal article J Am Coll Cardiol · September 18, 2007 OBJECTIVES: We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP). BACKGROUND: The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 m ... Full text Link to item Cite

Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.

Journal article Ann Thorac Surg · September 2007 BACKGROUND: The presence of heparin-induced thrombocytopenia (HIT) increases the risk for thromboembolic events in ventricular assist device (VAD) patients undergoing transplantation. However, cardiopulmonary bypass with alternative anticoagulants is often ... Full text Link to item Cite

Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies.

Journal article Am J Clin Pathol · July 2007 Heparin-induced thrombocytopenia is a life threatening thrombotic disorder caused by antibodies to platelet factor 4 (PF4) and heparin. Commercial immunoassays are frequently used for the detection of PF4-heparin antibodies, and several studies have report ... Full text Link to item Cite

Invited commentary.

Journal article Ann Thorac Surg · July 2007 Full text Link to item Cite

Age and dose sensitivities in the 2-butoxyethanol F344 rat model of hemolytic anemia and disseminated thrombosis.

Journal article Exp Toxicol Pathol · April 2007 In hemolytic disorders, such as sickle cell disease and beta-thalassemia, the mechanisms of thrombosis are poorly understood. Appropriate animal models would increase the understanding of the pathophysiology of thrombosis. We previously reported that rats ... Full text Link to item Cite

The U.S. Thrombosis and Hemostasis Centers pilot sites program.

Journal article J Thromb Thrombolysis · February 2007 Venous thromboembolism (VTE) is a common disorder associated with significant morbidity and mortality. Despite important advances in understanding the etiology of VTE, delivery of care to patients with thrombosis and thrombophilia is frequently incomplete ... Full text Link to item Cite

The authors reply [21]

Journal article New England Journal of Medicine · December 14, 2006 Full text Cite

A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.

Journal article Thromb Haemost · December 2006 Low-molecular-weight heparins undergo renal elimination, and therefore the proper dosing in hemodialysis (HD) patients is unclear. It was the objective of this study to evaluate the pharmacokinetic (PK) parameters of dalteparin in patients receiving chroni ... Link to item Cite

Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves.

Journal article J Matern Fetal Neonatal Med · September 2006 BACKGROUND: Pregnancy in a woman with a mechanical heart valve is a life-threatening situation. Due to the inability of unfractionated heparin to prevent valvular thromboses, warfarin or other vitamin K antagonists have been the preferred anticoagulants fo ... Full text Link to item Cite

Clinical practice. Heparin-induced thrombocytopenia.

Journal article N Engl J Med · August 24, 2006 Full text Link to item Cite

The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery.

Journal article J Cardiothorac Vasc Anesth · August 2006 OBJECTIVE: The objective of this study was to determine the relationship of the kaolin-activated Thrombelastograph (TEG) with postoperative bleeding and laboratory tests of coagulation in the setting of cardiac surgery with the routine use of -aminocaproic ... Full text Link to item Cite

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Journal article J Thromb Haemost · June 2006 BACKGROUND: Patients who receive long-term oral anticoagulant (OAC) therapy often require interruption of OAC for an elective surgical or an invasive procedure. Heparin bridging therapy has been used in these situations, although the optimal method has not ... Full text Link to item Cite

Gene-expression patterns predict phenotypes of immune-mediated thrombosis.

Journal article Blood · February 15, 2006 Antiphospholipid antibody syndrome (APS) is a complex autoimmune thrombotic disorder with defined clinical phenotypes. Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complications, the severity of these potential ev ... Full text Link to item Cite

Thrombophilia in pregnancy: Maternal and fetal implications

Journal article Current Women S Health Reviews · February 1, 2006 Pregnancy is accompanied by altered levels of coagulation factors, which are likely responsible for an increased risk of thrombosis, including an increased risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction. Women with throm ... Full text Cite

Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.

Journal article J Thromb Haemost · February 2006 BACKGROUND: Closure time (CT), measured by platelet function analyzer (PFA-100) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time test. AIM: On behalf of the Platelet Physiology Subcommittee of ... Full text Link to item Cite

The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it?

Journal article J Thromb Thrombolysis · February 2006 The antiphospholipid syndrome is described with a review of its historical development as a recognized syndrome, what constitutes an antiphospholipid antibody, how it is measured, and how the syndrome is treated. Antiphospholipid antibodies are actually an ... Full text Link to item Cite

Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure.

Journal article Am J Physiol Lung Cell Mol Physiol · January 2006 Tissue factor expression in sepsis activates coagulation in the lung, which potentiates inflammation and leads to fibrin deposition. We hypothesized that blockade of factor X binding to the tissue factor-factor VIIa complex would prevent sepsis-induced dam ... Full text Link to item Cite

Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis.

Journal article Thromb Res · 2006 INTRODUCTION: In hemolytic diseases such as sickle cell disease and beta-thalassemia, the mechanisms of thrombosis are poorly understood, however erythrocyte/endothelium interactions are thought to play an important role. Appropriate animal models would in ... Full text Link to item Cite

Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery.

Journal article J Thorac Cardiovasc Surg · December 2005 OBJECTIVE: Preexisting serum antibodies to heparin/platelet factor 4 complexes may predispose adult cardiac surgical patients to increased perioperative morbidity and mortality. We sought to determine the association between preoperative serum antibodies d ... Full text Link to item Cite

Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.

Journal article Thromb Haemost · December 2005 Antiphospholipid antibodies can influence the results of clotting tests in a subset of patients, which can be a major obstacle in monitoring warfarin. The aim was to determine if point-of-care testing of the International Normalized Ratio (INR) is influenc ... Full text Link to item Cite

Thrombophilia and thrombosis in thrombotic thrombocytopenic purpura.

Journal article Semin Thromb Hemost · December 2005 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia often accompanied by microvascular ischemia, which may manifest as sensorimotor signs, visual changes, renal im ... Full text Link to item Cite

Thrombosis Research: Preface

Journal article Thrombosis Research · November 18, 2005 Full text Cite

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Journal article Science · June 24, 2005 The design of a human immunodeficiency virus-1 (HIV-1) immunogen that can induce broadly reactive neutralizing antibodies is a major goal of HIV-1 vaccine development. Although rare human monoclonal antibodies (mAbs) exist that broadly neutralize HIV-1, HI ... Full text Link to item Cite

Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII.

Journal article Thromb Haemost · May 2005 Factor VIII binds to phospholipid membranes through the C2 domain (S2173-Y2332). Residues M2199, F2200, L2251, L2252, V2223, W2313 and V2314 at the tips of beta-hairpins and loops are thought to contribute to phospholipid membrane binding. Similarly, resid ... Full text Link to item Cite

von Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine system.

Journal article Obstet Gynecol · May 2005 BACKGROUND: Adult females with menorrhagia may have unrecognized mild von Willebrand's disease. Most females with known von Willebrand's disease report menorrhagia. CASE: A 38-year-old healthy female desired contraception. She described heavy menses lastin ... Full text Link to item Cite

Antihuman factor V antibodies after use of relatively pure bovine thrombin.

Journal article Ann Thorac Surg · March 2005 Although bovine thrombin is commonly used in the operating room, there is evidence that exposure to bovine thrombin can result in the development of autoimmune antibodies, usually against factor V, which can lead to a profound coagulopathy. It is thought t ... Full text Link to item Cite

Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.

Journal article Clin Adv Hematol Oncol · March 2005 Normal pregnancy is accompanied by changes in coagulation that have likely evolved to protect women from the bleeding challenges of miscarriage and childbirth. Consequently, pregnant women are at an increased risk of thrombosis. The most important risk fac ... Link to item Cite

Warfarin in antiphospholipid syndrome--time to explore new horizons.

Journal article J Rheumatol · February 2005 Featured Publication Link to item Cite

Thrombosis and the antiphospholipid syndrome.

Journal article Hematology Am Soc Hematol Educ Program · 2005 The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. Several studies have determined that the frequency of antiphospholipid syndrome in patients presenting with a ... Full text Link to item Cite

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome.

Journal article Blood · November 1, 2004 Featured Publication Annexin A5 (A5) forms 2-dimensional crystals over phospholipid bilayers, blocking their availability for coagulation reactions. Recently, human antiphospholipid (aPL) monoclonal antibodies (mAbs) have been demonstrated by atomic force microscopy (AFM) to d ... Full text Link to item Cite

Regulatable aptamers in medicine: focus on antithrombotic strategies.

Journal article Expert Opin Biol Ther · October 2004 Featured Publication Proteins generally execute the key physiological activities required for normal growth and homeostasis. As such, many different classes of proteins, including proteases, kinases, cellular receptors and signalling proteins, represent attractive targets for ... Full text Link to item Cite

Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.

Journal article Am J Obstet Gynecol · August 2004 Featured Publication OBJECTIVE: The purpose of this study was to assess the usefulness of a new platelet function analyzer in the detection of von Willebrand disease and platelet dysfunction in women with menorrhagia. STUDY DESIGN: Women with menorrhagia and control subjects w ... Full text Link to item Cite

Coagulation abnormalities in patients with hip osteonecrosis.

Journal article Orthop Clin North Am · July 2004 The relatively high frequency of coagulation abnormalities in patients with hip osteonecrosis might represent increased risk factors for the development of bone necrosis by predisposing these patients to thromboembolic phenomena. The recognition of this as ... Full text Link to item Cite

A review of the therapeutic uses of thrombin.

Journal article Thromb Haemost · May 2004 Featured Publication Thrombin is the product of the hemostatic response essential to the conversion of fibrinogen to fibrin. In addition, it is also responsible for the aggregation of blood platelets in the formation of the "platelet plug" as well as the activation of factor V ... Full text Link to item Cite

Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.

Journal article Blood Coagul Fibrinolysis · September 2003 A patient with antiphospholipid antibody syndrome (APS) and a history of heparin-induced thrombocytopenia required lepirudin therapy. The patient had an abnormal baseline activated partial thromboplastin time (aPTT), complicating management of his therapy. ... Full text Link to item Cite

Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis.

Journal article J Vasc Surg · September 2003 Featured Publication Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoagulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic anticoagulation ... Full text Link to item Cite

Prothrombin and beta 2-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assays.

Journal article Thromb Haemost · August 2003 Transmittance waveforms are generated during clot formation on photo-optical coagulation analyzers. We previously showed that 61.5% of patients with antiphospholipid antibodies (APLA) exhibited a negative deflection in the pre-coagulation phase of the prot ... Full text Link to item Cite

Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.

Journal article Blood Coagul Fibrinolysis · June 2003 We characterized seven factor VIII inhibitors with epitopes in the C2 domain of factor VIII using a series of factor V C2 domain chimeras that substituted exon-sized fragments of the C2 domain of factor VIII for the corresponding regions of factor V. All i ... Full text Link to item Cite

Heparin-induced thrombocytopenia: clinical presentations and therapeutic management.

Journal article Clin Adv Hematol Oncol · June 2003 With increasing indications for heparin usage, an understanding of heparin-induced thrombocytopenia (HIT) as a complication of heparin therapy is more essential than ever. Complications of HIT can result in significant morbidity and mortality. We review th ... Link to item Cite

Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.

Journal article Thromb Haemost · May 2003 Featured Publication The crystal structure of the factor VIII C2 domain consists of a beta-sandwich core from which beta-hairpins and loops extend to form a hydrophobic surface. The hydrophobic surface includes M2199 and F2200 at the tip of the 1(st) beta-hairpin. To determine ... Link to item Cite

Blockade of tissue factor: treatment for organ injury in established sepsis.

Journal article Am J Respir Crit Care Med · May 1, 2003 Blockade of tissue factor before lethal sepsis prevents acute lung injury and renal failure in baboons, indicating that activation of coagulation by tissue factor is an early event in the pathogenesis of acute lung injury and organ dysfunction. We hypothes ... Full text Link to item Cite

Clinical and laboratory evaluation of thrombophilia.

Journal article Clin Chest Med · March 2003 Thrombophilia is the predisposition to venous thromboembolism and is caused by inherited and acquired factors, alone or in combination. With the discovery of APC resistance and the prothrombin gene mutation, more than half of all patients with clinical cha ... Full text Link to item Cite

Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.

Journal article Semin Dial · 2003 Dialysis patients who are continually exposed to heparin are at risk for heparin-induced thrombocytopenia (HIT). Heparin-induced antibodies have been reported to occur in 0-12% of hemodialysis (HD) patients. The diagnosis or suspicion of HIT in this patien ... Full text Link to item Cite

Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids.

Journal article Thromb Haemost · October 2002 Featured Publication To clarify the role(s) of anti-beta(2) GPI antibodies on thrombosis in anti-phospholipid antibody syndromes (APS), the effect of IgG from three patients on activated protein C (APC) was investigated using phospholipid vesicles and purified proteins. Two of ... Link to item Cite

Anti-β2-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β2-glycoprotein I to phospholipids

Journal article Thrombosis and Haemostasis · October 1, 2002 To clarify the role(s) of anti-β2GPI antibodies on thrombosis in antiphospholipid antibody syndromes (APS), the effect of IgG from three patients on activated protein C (APC) was investigated using phospholipid vesicles and purified proteins. Tw ... Full text Cite

RNA aptamers as reversible antagonists of coagulation factor IXa.

Journal article Nature · September 5, 2002 Featured Publication Many therapeutic agents are associated with adverse effects in patients. Anticoagulants can engender acute complications such as significant bleeding that increases patient morbidity and mortality. Antidote control provides the safest means to regulate dru ... Full text Link to item Cite

Antiphospholipid antibodies.

Journal article Arch Intern Med · August 12, 2002 Full text Link to item Cite

Issues in the utilization of low molecular weight heparins.

Journal article Semin Hematol · July 2002 Low molecular weight heparins (LMWHs) are parenteral anticoagulants that are widely used for the prevention and treatment of thromboembolic disease. These agents possess several advantages compared to standard heparin, including a more predictable anticoag ... Full text Link to item Cite

Coagulation and inflammation in acute lung injury.

Journal article Thromb Haemost · July 2002 The acute respiratory distress syndrome (ARDS) is a severe lung injury in patients with sepsis and other acute inflammatory insults, which is characterized by fibrin deposition in the pulmonary parenchyma, vasculature, and airspaces. Recent evidence sugges ... Link to item Cite

Antiphospholipid antibodies after surgical exposure to topical bovine thrombin.

Journal article J Lab Clin Med · June 2002 Featured Publication Exposure to topical bovine thrombin during surgery frequently results in the development of antibodies to multiple protein and carbohydrate antigens. We investigated the frequency of increased levels of antibodies to cardiolipin and beta(2)-glycoprotein I ... Full text Link to item Cite

Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.

Journal article Blood · April 15, 2002 Featured Publication Most plasmas from patients with inhibitors contain antibodies that are reactive with the C2 domain of factor VIII. Previously, we have shown that the variable heavy chain (V(H)) regions of antibodies to the C2 domain are encoded by the closely related germ ... Full text Link to item Cite

Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies.

Journal article Blood Coagul Fibrinolysis · January 2002 Transmittance waveforms are the optical data generated during clot formation on photo-optical coagulation analyzers and are used to define specific events of the clotting reactions. Thus, a prothrombin time (PT) or an activated partial thromboplastin time ... Full text Link to item Cite

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis.

Journal article Am J Hematol · January 2002 Heparin-induced thrombocytopenia (HIT), characterized by the formation of antibodies to a complex of platelet factor 4 (PF4) and heparin, is a well-recognized risk factor for thromboembolic complications. The frequency of antibody development varies among ... Full text Link to item Cite

Anti-β2-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β2-glycoprotein I to phospholipids

Journal article Thrombosis and Haemostasis · 2002 To clarify the role(s) of anti-β2GPI antibodies on thrombosis in antiphospholipid antibody syndromes (APS), the effect of IgG from three patients on activated protein C (APC) was investigated using phospholipid vesicles and purified proteins. Two of the to ... Cite

Mutation of bcl-x gene in non-Hodgkin's lymphoma.

Journal article Am J Hematol · January 2002 The bcl-x gene product has two forms, bcl-xl and bcl-xs. The bcl-xl form, similar to bcl-2, inhibits apoptosis. Reverse transcriptase-polymerase chain reaction/single-stranded conformation polymorphism (RT-PCR-SSCP) gel analysis was used to screen for muta ... Full text Link to item Cite

Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons.

Journal article Am J Respir Crit Care Med · November 15, 2001 Sepsis-induced tissue factor (TF) expression activates coagulation in the lung and leads to a procoagulant environment, which results in fibrin deposition and potentiates inflammation. We hypothesized that preventing initiation of coagulation at TF-Factor ... Full text Link to item Cite

Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Journal article Am J Pathol · November 2001 Bovine thrombin is used as an aid to hemostasis in medical and surgical procedures. At least 500,000 Americans are exposed to this therapeutic annually and reports suggest that exposure is associated with the development of autoreactive antibodies. To dete ... Full text Link to item Cite

Tissue factor in experimental acute lung injury.

Journal article Semin Hematol · October 2001 Acute lung injury (ALI) is characterized by fibrin deposition in the tissue and vascular spaces. Coagulation is activated after exposure to endotoxin or bacteria, and a procoagulant environment rapidly develops in the vascular, interstitial, and alveolar s ... Full text Link to item Cite

Risk factors associated with thrombosis in patients with antiphospholipid antibodies.

Journal article J Rheumatol · September 2001 Featured Publication OBJECTIVE: To define risk factors associated with thrombosis in patients with antiphospholipid antibodies (aPL). METHODS: Ninety-nine patients with aPL, most of whom had prior thrombosis, were evaluated for the presence of acquired and inherited thrombophi ... Link to item Cite

Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.

Journal article Thromb Haemost · August 2001 Many of the autoantibodies in antiphospholipid syndrome (APS) are directed against beta2-glycoprotein I (beta2-GPI). Recent studies from our laboratories have indicated that the immunodominant binding epitope(s) for high titer, affinity purified antibodies ... Link to item Cite

Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding.

Journal article Thromb Haemost · June 2001 Featured Publication Hemorrhagic factor V inhibitors frequently bind to the second C-type (C2) domain of factor V and interfere with phospholipid binding. To define specific residues recognized by inhibitors from four patients (one bovine thrombin-induced and three spontaneous ... Link to item Cite

Factor VIII Arg2304 --> His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex.

Journal article Thromb Haemost · February 2001 Featured Publication Four factor VIII light chain constructs containing hemophilia A mutations at R2304 and R2307 were prepared and expressed in mammalian cells. These mutations are located in a putative phosphatidylserine binding site identified by peptide studies (spanning a ... Link to item Cite

β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I

Journal article Thrombosis and Haemostasis · January 1, 2001 Many of the autoantibodies in antiphospholipid syndrome (APS) are directed against β2-glycoprotein I (β2-GPI). Recent studies from our laboratories have indicated that the immunodominant binding epitope(s) for high titer, affinity pur ... Full text Cite

Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis.

Journal article ASAIO J · 2001 We studied 88 hemodialysis patients for the presence of antibodies to human factor II (hFII), bovine factor V (bFV), and human beta2-glycoprotein 1 (beta2GPI). Forty-one patients had elevated anti-hFII antibodies, 17 had elevated anti-bFV antibodies, and 9 ... Full text Link to item Cite

Anticoagulation therapy.

Journal article Hematology Am Soc Hematol Educ Program · 2001 Despite refinements and standardization in the use of anticoagulants, many problems remain for clinicians. Dr. Crowther describes appropriate starting and maintenance doses of warfarin, factors accounting for inter- and intra-observer variability and impor ... Full text Link to item Cite

Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.

Journal article Ann Surg · January 2001 Featured Publication OBJECTIVE: To determine prospectively the immunologic response and adverse clinical events in surgical patients exposed to bovine thrombin during cardiac surgical procedures. SUMMARY BACKGROUND DATA: Topical bovine thrombin is used extensively as a hemosta ... Full text Link to item Cite

Tissue factor in experimental acute lung injury

Journal article Seminars in Hematology · January 1, 2001 Acute lung injury (ALI) is characterized by fibrin deposition in the tissue and vascular spaces. Coagulation is activated after exposure to endotoxin or bacteria, and a procoagulant environment rapidly develops in the vascular, interstitial, and alveolar s ... Full text Cite

β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I

Journal article Thrombosis and Haemostasis · 2001 Many of the autoantibodies in antiphospholipid syndrome (APS) are directed against β2-glycoprotein I (β2-GPI). Recent studies from our laboratories have indicated that the immunodominant binding epitope(s) for high titer, affinity purified antibodies from ... Cite

Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.

Journal article Nat Genet · September 2000 May-Hegglin anomaly (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia, giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal, suggesting ... Full text Link to item Cite

Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center.

Journal article Thromb Haemost · July 2000 We evaluated the utility of the PFA-100 platelet function analyzer in identifying disorders in platelet function and/or von Willebrand factor (vWF) in patients with various systemic disorders being followed at a tertiary care center. Closure times were det ... Link to item Cite

Antibodies to topical bovine thrombin correlate with access thrombosis.

Journal article Am J Kidney Dis · May 2000 Bovine thrombin is often used topically to promote hemostasis during vascular surgery, including dialysis-access placement. Patients frequently develop antibodies to bovine thrombin preparations, and some may develop antiphospholipid antibodies. We evaluat ... Full text Link to item Cite

Antibodies to prothrombin and factor V correlate-with PTFE graft thrombosis

Journal article ASAIO Journal · January 1, 2000 In this study, 88 hemodialysis patients (44 AV fistulas [AVF], 28 PTFE grafts [PTFE], 16 cuffed catheters [CC]) were studied for the presence of antibodies to human and bovine prothrombin (FII), bovine factor V (bFV), and human β2-glycoprotein I ... Full text Cite

Crystal structures of the membrane-binding C2 domain of human coagulation factor V.

Journal article Nature · November 25, 1999 Rapid and controlled clot formation is achieved through sequential activation of circulating serine proteinase precursors on phosphatidylserine-rich procoagulant membranes of activated platelets and endothelial cells. The homologous complexes Xase and prot ... Full text Link to item Cite

Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.

Journal article Biochemistry · August 31, 1999 Thrombin-activated factor Va exists as two isoforms, factor Va(1) and factor Va(2), which differ in the size of their light chains and their affinity for biological membranes. The heterogeneity of the light chain remained following incubation of factor Va ... Full text Link to item Cite

Clinical and laboratory manifestations of anti-factor V antibodies.

Journal article J Lab Clin Med · April 1999 Factor V is a large, multi-domain glycoprotein that exhibits both procoagulant and anticoagulant activity. Anti-factor V antibodies may develop by several mechanisms and, depending on their epitope specificity, may produce hemorrhagic or thromboembolic com ... Full text Link to item Cite

Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.

Journal article Pharmacotherapy · April 1999 STUDY OBJECTIVE: To measure the difference in therapeutic ranges of activated partial thromboplastin time (APTT) between two laboratory devices. DESIGN: Prospective, controlled laboratory study. SETTING: University-affiliated hospital. PATIENTS: Thirty inp ... Full text Link to item Cite

Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance.

Journal article Arthritis Rheum · February 1999 Featured Publication OBJECTIVE: To develop diagnostic criteria for a familial form of antiphospholipid antibody syndrome (APS), identify families with >1 affected member, examine possible modes of inheritance, and determine linkage to potential candidate genes. METHODS: Family ... Full text Link to item Cite

New treatment options for heparin-induced thrombocytopenia

Journal article Seminars in Hematology · December 14, 1998 A rapidly acting anticoagulant that can either inhibit thrombin generation or inhibit thrombin itself is the optimum therapy for acute thrombosis associated with heparin-induced thrombocytopenia (HIT). In this review, the newer treatment approaches that fu ... Cite

Diagnosis of pulmonary embolism.

Journal article N Engl J Med · October 8, 1998 Link to item Cite

New treatment options for heparin-induced thrombocytopenia.

Journal article Semin Hematol · October 1998 A rapidly acting anticoagulant that can either inhibit thrombin generation or inhibit thrombin itself is the optimum therapy for acute thrombosis associated with heparin-induced thrombocytopenia (HIT). In this review, the newer treatment approaches that fu ... Link to item Cite

Heparin-induced thrombocytopenia.

Journal article Semin Hematol · October 1998 Link to item Cite

Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.

Journal article Pediatr Radiol · August 1998 The purpose of this report is to describe imaging findings in activated protein C resistance, a hereditary cause of recurrent thrombosis. The case described was unusual in that a neonate was affected, whereas the vast majority of cases occur in adulthood. ... Full text Link to item Cite

Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.

Journal article Blood · June 1, 1998 Factor V inhibitors may develop as spontaneous autoantibodies, as alloantibodies after exposure to bovine thrombin preparations, or in factor V-deficient patients after plasma therapy. Clinical manifestations range from asymptomatic laboratory abnormalitie ... Link to item Cite

Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.

Journal article Radiology · April 1998 PURPOSE: To assess the patterns of abnormal neuroradiologic findings in patients with a hypercoagulable state related to activated protein C (APC) resistance. MATERIALS AND METHODS: Records in 23 patients with a hypercoagulable state related to APC resista ... Full text Link to item Cite

Antiphospholipid antibodies: findings at arteriography.

Journal article AJNR Am J Neuroradiol · April 1998 PURPOSE: The purpose of this study was to determine the frequency and types of abnormalities at arteriography in patients with antiphospholipid antibodies (APA) and ischemic cerebrovascular events. METHODS: Twenty-three patients with APA and ischemic cereb ... Link to item Cite

Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.

Journal article AJR Am J Roentgenol · February 1998 OBJECTIVE: The purpose of this study was to report the association of dural sinus thrombosis with a hypercoagulable state associated with activated protein C resistance. CONCLUSION: In our small study population, hemorrhagic venous infarction was common (t ... Full text Link to item Cite

Disseminated thrombosis in primary antiphospholipid syndrome: MR findings.

Journal article Eur J Radiol · February 1998 We report the MR imaging findings in a patient with primary antiphospholipid syndrome, adrenal infarction and widespread thrombosis involving abdominal, pelvic, and pulmonary vessels. This syndrome should be suspected in patients with thromboses and organ ... Full text Link to item Cite

Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings.

Journal article AJR Am J Roentgenol · February 1998 OBJECTIVE: The purpose of this study was to determine the patterns of non-CNS thromboses in patients with a hypercoagulable state associated with antiphospholipid antibodies (APA). MATERIALS AND METHODS: A search of our institution's clinical coagulation a ... Full text Link to item Cite

Anticardiolipin antibodies and osteonecrosis of the femoral head.

Journal article Clin Orthop Relat Res · December 1997 The current study evaluated the prevalence of anticardiolipin antibodies, which have been associated with thrombotic phenomena, in patients with nontraumatic osteonecrosis of the hip and assessed whether the presence of such antibodies is associated with a ... Link to item Cite

Monitoring warfarin therapy in patients with lupus anticoagulants.

Journal article Ann Intern Med · August 1, 1997 BACKGROUND: Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothr ... Full text Link to item Cite

Subdural hematoma and lupus anticoagulants.

Journal article Stroke · March 1997 BACKGROUND AND PURPOSE: Patients with lupus anticoagulants do not typically have a bleeding tendency. However, a few reports of hemorrhage in patients with lupus anticoagulants in the absence of known risk factors for bleeding have been published, raising ... Full text Link to item Cite

Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.

Journal article Blood Coagul Fibrinolysis · January 1997 Monitoring of oral anticoagulant therapy is usually undertaken with the prothrombin time (PT), which is influenced by factors II, X, and VII. A number of studies have suggested that the prothrombin (factor II) level may be the most important determinant of ... Full text Link to item Cite

Helical computed tomography and magnetic resonance imaging in the diagnosis of venous thromboembolic disease: Case report and review of the literature

Journal article Clinical Pulmonary Medicine · January 1, 1997 Pulmonary embolism (PE) remains a common cause of morbidity and mortality. Appropriate therapy requires timely diagnosis, but currently available noninvasive modalities lack adequate sensitivity and specificity. In particular, the vast majority of ventilat ... Full text Cite

Thrombocytopenia in association with a wandering spleen.

Journal article Am J Hematol · December 1996 An ectopic, so-called wandering spleen is an uncommon occurrence. We present the case of a young woman who presented with abdominal pain and was found to have an enlarged spleen, located in the lower abdomen and pelvis. The possibility of lymphoma was ente ... Full text Link to item Cite

Patients with antiphospholipid antibodies: CT and MR findings of the brain.

Journal article AJR Am J Roentgenol · December 1996 OBJECTIVE: The purpose of this study was to determine the spectrum of neuroradiologic findings in patients with antiphospholipid antibodies (APA) and to compare findings in systemic lupus erythematosus (SLE) and non-SLE patients. MATERIALS AND METHODS: We ... Full text Link to item Cite

Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII.

Journal article Thromb Haemost · January 1996 Factor VIII and factor V share a repetitive domain structure of A1-A2-B-A3-C1-C2. To define the region(s) within the factor VIII heavy chain that result in inefficient expression of the recombinant protein, we expressed a series of factor VIII/factor V chi ... Link to item Cite

Factor v inhibitors associated with hemorrhagic symptoms bind to a limited region of the factor va light chain

Journal article Journal of Investigative Medicine · January 1, 1996 Factor V inhibitors most commonly occur as (1 ) spontaneously arising autoantibodies in previously normal patients, or (2) cross-reacting alloantibodies arising after exposure to topical bovine thrombin preparations containing bovine factor V. We previousl ... Cite

Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings.

Journal article AJR Am J Roentgenol · August 1995 OBJECTIVE: Antiphospholipid antibodies are immunoglobulins that cross-react with phospholipid within cell membranes. These antibodies have been associated with a hypercoagulable state manifested by early stroke, frequent arterial and venous thromboses, rec ... Full text Link to item Cite

Adrenal hemorrhage in patients with primary antiphospholipid syndrome: imaging findings.

Journal article AJR Am J Roentgenol · August 1995 OBJECTIVE: The primary antiphospholipid syndrome consists of recurrent thromboses, early stroke, recurrent fetal loss, and livedo reticularis in patients with antiphospholipid antibodies and without systemic lupus erythematosus. The purpose of this study w ... Full text Link to item Cite

Clinical and laboratory evaluation of the hypercoagulable states.

Journal article Clin Chest Med · June 1995 In summary, every patient presenting with a new (or recurrent) thromboembolic event should be carefully assessed for potential predisposing factors. This starts with a thorough patient history and complete physical examination. If indicated, the clinical a ... Link to item Cite

Thrombin-catalyzed activation of recombinant human factor V.

Journal article Biochemistry · March 28, 1995 Proteolytic activation of human factor V by thrombin results from the cleavage of three peptide bonds at Arg709, Arg1018, and Arg1545. In order to define the functional importance of these sites, mutants with isoleucine substitutions blocking thrombin clea ... Full text Link to item Cite

A Sensitive DRVVT Reagent System for the Detection of Lupus Anticoagulants

Journal article Clinical and Applied Thrombosis Hemostasis · January 1, 1995 Lupus anticoagulants are antibodies that inter fere with the phospholipid-dependent steps in in vitro blood clotting. The dilute viper venom (DVV)test is a phospholipid-limiting assay in which a plasma sample is preactivated with the venom from the pit vip ... Full text Cite

Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2.

Journal article Clin Chem · October 1994 We have used a monoclonal antibody-based ELISA for plasma prothrombin fragment 1.2 (F1.2) to establish appropriate sample collection and storage conditions for this biomarker of thrombin generation. F1.2 concentrations were not altered by exogenous factor ... Link to item Cite

Evaluation of a modified procedure for Staclot LA for the confirmation of lupus anticoagulants.

Journal article Blood Coagul Fibrinolysis · August 1994 Staclot LA is a hexagonal (II) phase phospholipid clotting assay used to confirm the presence of lupus anticoagulants (LA). However, there have been complaints that the procedure contains several incubation steps requiring 15 min of operator time. The auth ... Link to item Cite

Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings.

Journal article Radiology · August 1994 PURPOSE: To study neuroradiologic findings in patients with hypercoagulability due to antiphospholipid antibodies (APAs). MATERIALS AND METHODS: Retrospective review of abnormal angiographic, computed tomographic, and magnetic resonance imaging findings wa ... Full text Link to item Cite

Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.

Journal article J Biol Chem · June 3, 1994 Coagulation factor V, an integral component of the prothrombinase complex, possesses two C-type domains at the carboxyl-terminal end of the molecule. Homologous C-type domains are present in factor VIII as well as several non-coagulation proteins. Deletion ... Link to item Cite

Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.

Journal article Am J Hematol · February 1994 Topical bovine thrombin preparations are used extensively in cardiovascular, neurosurgical, and otolaryngologic procedures. Patients who are treated with these topical thrombin preparations may develop antibodies to bovine coagulation factors that may cros ... Full text Link to item Cite

Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.

Journal article Blood · August 15, 1993 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem-cell disorder in which the glycolipid-anchored membrane proteins, including the cell-surface complement inhibitors, CD55 and CD59, are partially or completely deleted from the plasma membranes o ... Link to item Cite

Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Journal article J Clin Invest · December 1992 Coagulation Factor V is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. A patient was described who developed a Factor V inhibitor that neutralized the procoagulant activity of Factor V and resulte ... Full text Link to item Cite

Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.

Journal article Thromb Haemost · March 2, 1992 Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiatio ... Link to item Cite

Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain.

Journal article J Biol Chem · February 25, 1992 Human coagulation factor V is an integral component of the prothrombinase complex. Rapid activation of prothrombin is dependent on the interactions of this nonenzymatic cofactor with factor Xa and prothrombin in the presence of calcium ions and a phospholi ... Link to item Cite

"Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.

Journal article Anesthesiology · September 1990 Org 10172 provided adequate anticoagulation for this patient. An excellent correlation between anti-factor Xa activity and ACT was observed at the doses used for CPB. If high-dose Org 10172 is used, these data suggest that it may be possible to circumvent ... Link to item Cite

Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region.

Journal article Biochemistry · July 24, 1990 Human coagulation factor V is a protein cofactor that is an essential component of the prothrombinase complex. A full-length factor V cDNA has been subcloned into the mammalian expression vector pDX and used to transfect COS cells. Approximately 95 +/- 4% ... Full text Link to item Cite

Group C streptococcal arthritis: case report and review.

Journal article Rev Infect Dis · 1990 Streptococci account for approximately 15%-20% of cases of nongonococcal septic arthritis. The majority of these are due to group A streptococci, but group B and group G streptococci are being isolated more frequently. We present a case of group C streptoc ... Full text Link to item Cite

Author's reply

Journal article American Journal of Hematology · January 1, 1989 Full text Cite

Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome.

Journal article Am J Hematol · September 1988 The Kasabach Merritt syndrome consists of thrombocytopenia, microangiopathic hemolytic anemia, and a localized consumption coagulopathy that develops within the abnormal vascular channels of a hemangioma. In general, these patients demonstrate only mild ab ... Full text Link to item Cite

Arsenic poisoning and seizures.

Journal article N C Med J · December 1987 Link to item Cite

Purification of glycopeptides of human plasma proteins by high-performance liquid chromatography.

Journal article J Chromatogr · December 28, 1984 The combination of gel permeation chromatography and high-performance liquid chromatography proves to be very effective for the purification of high-molecular-weight glycopeptides containing a single glycan, that have been difficult to separate by other pr ... Full text Link to item Cite

Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains.

Journal article Proc Natl Acad Sci U S A · August 1984 A molecular model for the structure of human ceruloplasmin is proposed that is based on the determination of the complete amino acid sequence, studies of the products of limited proteolytic cleavage, calculations of the hydrophilic/hydrophobic character (h ... Full text Link to item Cite

Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule.

Journal article Proc Natl Acad Sci U S A · January 1984 We have determined the amino acid sequence of the amino-terminal 67,000-dalton (67-kDa) fragment of human ceruloplasmin and have established overlapping sequences between the 67-kDa and 50-kDa fragments and between the 50-kDa and 19-kDa fragments. The 67-k ... Full text Link to item Cite

Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains

Journal article Proceedings of the National Academy of Sciences of the United States of America · 1984 A molecular model for the structure of human ceruloplasmin is proposed that is based on the determination of the complete amino acid sequence, studies of the products of limited proteolytic cleavage, calculations of the hydrophilic/hydrophobic character (h ... Cite

Separation of limited tryptic fragments of human ceruloplasmin by gel-permeation high-performance liquid chromatography.

Journal article J Chromatogr · August 26, 1983 Limited tryptic proteolysis of human ceruloplasmin rapidly produces several large, protease-resistant fragments, suggesting that the molecule consists of several domains. In order to locate the sites of proteolytic cleavage in the whole molecule, we used g ... Full text Link to item Cite

Internal triplication in the structure of human ceruloplasmin.

Journal article Proc Natl Acad Sci U S A · January 1983 Amino acid sequence analysis of the 67,000-dalton (67-kDal) fragment that is the amino-terminal half of human ceruloplasmin has revealed internal triplication in the primary structure of the entire molecule. This is illustrated by comparison of 620 residue ... Full text Link to item Cite